Journal article
The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations
Abstract
In 2007, the results from a meta analysis of 29 clinical studies indicated that tegaserod (Zelnorm®), a 5-hydroxytryptamine4 (5-HT4) receptor agonist with gastrointestinal prokinetic activity, was associated with an increased incidence of cardiovascular ischemic events, resulting in its withdrawal from many markets around the world. Stimulation of platelet aggregation has been proposed to explain the phenomenon. However, data from recent …
Authors
Higgins DL; Ero MP; Loeb M; Kersey K; Hopkins A; Beattie DT
Journal
Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 385, No. 1, pp. 103–109
Publisher
Springer Nature
Publication Date
January 2012
DOI
10.1007/s00210-011-0687-x
ISSN
0028-1298